Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
type
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered question first ministerially corrected answering member label attachment file name title previous answer version answering member constituency answering member printed answering member label
tabling member	label

Search

100886

	registered interest
	date	24/10/2014
	answering body	Cabinet Office
	answering dept id	53
	answering dept short name	Cabinet Office
	answering dept sort name	Cabinet Office
	hansard heading	Asthma
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Minister for the Cabinet Office, how many people (a) under and (b) over the age of 18 died as a result of asthma in each of the last five years.
	tabling member constituency	Leicester West
	tabling member printed	Liz Kendall
	type	WrittenParliamentaryQuestion
	uin	211917
	answer	answer is ministerial correction date of answer 29/10/2014 answer text <p>The information requested falls within the responsibility of the UK Statistics Authority. I have asked the Authority to reply.</p><p> </p> answering member constituency Reading East answering member printed Mr Rob Wilson question first answered 29/10/2014 16:57:49 answering member 1556 label Biography information for Mr Rob Wilson attachment 1 file name PQ 211917 ONS 369.pdf title ONS Letter to Member - Death from Asthma
	tabling member	4026 label Biography information for Liz Kendall

100720

	registered interest
	date	23/10/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Osteoporosis: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, how much has been spent on prescriptions for the treatment of osteoporosis in each of the last five years.
	tabling member constituency	Leicester West
	tabling member printed	Liz Kendall
	type	WrittenParliamentaryQuestion
	uin	211731
	answer	answer is ministerial correction date of answer 30/10/2014 answer text <p>Information on National Health Service expenditure on drugs for the treatment of osteoporosis in primary and secondary care is in the table.</p><p> </p><p> </p><p> </p><p>Drugs for the treatment of osteoporosis have been defined as those included in the following British National Formulary sections:</p><p> </p><p>6.6 Drugs affecting bone metabolism</p><p> </p><p>9.5.1.1 Calcium supplements</p><p> </p><p>9.6 Vitamins (colecalciferol and ergocalciferol only)</p><p> </p><p><strong> </strong></p><p> </p><table><tbody><tr><td colspan="11"><p>Cost of drugs for the treatment of osteoporosis, England<sup>1</sup></p></td></tr><tr><td><p>Drug Name<sup>2</sup></p></td><td colspan="5"><p>Primary Care</p><p>(£ million)</p></td><td colspan="5"><p>Secondary Care</p><p>(£ million)</p></td></tr><tr><td><p>Year</p></td><td><p>2009</p></td><td><p>2010</p></td><td><p>2011</p></td><td><p>2012</p></td><td><p>2013</p></td><td><p>2009</p></td><td><p>2010</p></td><td><p>2011</p></td><td><p>2012</p></td><td><p>2013</p></td></tr><tr><td><p>Alendronic Acid</p></td><td><p>14.0</p></td><td><p>12.4</p></td><td><p>10.8</p></td><td><p>9.7</p></td><td><p>8.9</p></td><td><p>0.8</p></td><td><p>0.6</p></td><td><p>0.5</p></td><td><p>0.5</p></td><td><p>0.4</p></td></tr><tr><td><p>Alendronic Acid and Colecalciferol</p></td><td><p>1.4</p></td><td><p>1.2</p></td><td><p>0.9</p></td><td><p>0.7</p></td><td><p>0.6</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.0</p></td></tr><tr><td><p>Calcitonin (Salmon)</p></td><td><p>0.3</p></td><td><p>0.3</p></td><td><p>0.2</p></td><td><p>0.2</p></td><td><p>0.1</p></td><td><p>0.0</p></td><td><p>0.1</p></td><td><p>0.1</p></td><td><p>0.1</p></td><td><p>0.1</p></td></tr><tr><td><p>Calcium</p></td><td><p>4.2</p></td><td><p>4.7</p></td><td><p>4.5</p></td><td><p>3.7</p></td><td><p>3.3</p></td><td><p>0.9</p></td><td><p>0.9</p></td><td><p>0.9</p></td><td><p>0.9</p></td><td><p>0.9</p></td></tr><tr><td><p>Calcium and Colecalciferol</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>2.2</p></td><td><p>2.2</p></td><td><p>2.1</p></td><td><p>2.2</p></td><td><p>2.3</p></td></tr><tr><td><p>Clodronic Acid</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>2.9</p></td><td><p>2.4</p></td><td><p>1.6</p></td><td><p>1.2</p></td><td><p>0.9</p></td></tr><tr><td><p>Colecalciferol</p></td><td><p>42.4</p></td><td><p>48.3</p></td><td><p>58.5</p></td><td><p>67.6</p></td><td><p>75.0</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.4</p></td><td><p>1.2</p></td></tr><tr><td><p>Denosumab</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.2</p></td><td><p>0.8</p></td><td><p>1.9</p></td><td><p>0.0</p></td><td><p>0.1</p></td><td><p>0.9</p></td><td><p>2.3</p></td><td><p>9.9</p></td></tr><tr><td><p>Disodium Etidronate</p></td><td><p>1.3</p></td><td><p>1.0</p></td><td><p>0.8</p></td><td><p>0.6</p></td><td><p>0.3</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.0</p></td></tr><tr><td><p>Ergocalciferol</p></td><td><p>4.3</p></td><td><p>7.8</p></td><td><p>8.0</p></td><td><p>7.0</p></td><td><p>6.1</p></td><td><p>0.1</p></td><td><p>0.1</p></td><td><p>0.1</p></td><td><p>0.2</p></td><td><p>0.3</p></td></tr><tr><td><p>Ibandronic Acid</p></td><td><p>12.1</p></td><td><p>12.1</p></td><td><p>11.4</p></td><td><p>10.6</p></td><td><p>4.7</p></td><td><p>2.1</p></td><td><p>2.0</p></td><td><p>1.8</p></td><td><p>1.5</p></td><td><p>0.9</p></td></tr><tr><td><p>Pamidronic Acid</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>9.6</p></td><td><p>9.1</p></td><td><p>9.4</p></td><td><p>9.4</p></td><td><p>8.7</p></td></tr><tr><td><p>Risedronate Sodium and Risedronate Acid</p></td><td><p>27.9</p></td><td><p>22.9</p></td><td><p>11.6</p></td><td><p>2.4</p></td><td><p>2.0</p></td><td><p>0.8</p></td><td><p>0.6</p></td><td><p>0.3</p></td><td><p>0.1</p></td><td><p>0.1</p></td></tr><tr><td><p>Sodium Clodronate</p></td><td><p>7.8</p></td><td><p>7.2</p></td><td><p>6.3</p></td><td><p>5.5</p></td><td><p>4.3</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.0</p></td></tr><tr><td><p>Strontium Ranelate</p></td><td><p>7.0</p></td><td><p>7.8</p></td><td><p>9.0</p></td><td><p>9.2</p></td><td><p>7.3</p></td><td><p>0.6</p></td><td><p>0.6</p></td><td><p>0.6</p></td><td><p>0.5</p></td><td><p>0.2</p></td></tr><tr><td><p>Teriparatide</p></td><td><p>0.3</p></td><td><p>0.4</p></td><td><p>0.4</p></td><td><p>0.5</p></td><td><p>0.6</p></td><td><p>2.7</p></td><td><p>2.8</p></td><td><p>2.7</p></td><td><p>3.1</p></td><td><p>3.2</p></td></tr><tr><td><p>Zoledronic Acid</p></td><td><p>0.1</p></td><td><p>0.1</p></td><td><p>0.1</p></td><td><p>0.1</p></td><td><p>0.1</p></td><td><p>16.7</p></td><td><p>18.0</p></td><td><p>20.9</p></td><td><p>23.7</p></td><td><p>25.7</p></td></tr><tr><td><p>Other Calcium Supplement Preps</p></td><td><p>0.5</p></td><td><p>0.6</p></td><td><p>0.6</p></td><td><p>0.5</p></td><td><p>0.5</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.0</p></td></tr><tr><td><p>Other drugs<sup>3</sup></p></td><td><p>0.2</p></td><td><p>0.1</p></td><td><p>0.1</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.2</p></td><td><p>0.1</p></td><td><p>0.1</p></td><td><p>0.1</p></td><td><p>0.0</p></td></tr><tr><td><p>TOTAL</p></td><td><p>123.8</p></td><td><p>126.8</p></td><td><p>123.4</p></td><td><p>119.1</p></td><td><p>115.4</p></td><td><p>39.6</p></td><td><p>39.6</p></td><td><p>42.3</p></td><td><p>46.2</p></td><td><p>55.0</p></td></tr></tbody></table><p> </p><p><sup>1 </sup>Cost of drugs at NHS list price. It does not take account of discounts, dispensing costs, fees or prescription charges income. Totals may not add up due to rounding.</p><p> </p><p><sup>2</sup> The patent for some of these drugs may have expired during this period.</p><p> </p><p><sup>3</sup> “Other drugs” includes Calcium and Colecalciferol and Ergocalciferol, Calcium and Etidronic Acid, Calcium and Risedronic and Colecalciferol, Disodium Pamidronate, Ergocalciferol and Calcium, Etidronic Acid, Hydroxyapatite, Parathyroid Hormone, Salcatonin, Tiludronic Acid, other Bisphosphonate and other Preparations.</p><p> </p><p> </p><p> </p><p><em>Source: </em></p><p> </p><p>Prescription Cost Analysis (PCA) provided by the Health and Social Care Information Centre (primary care)</p><p> </p><p>Hospital Pharmacy Audit Index (HPAI) provided by IMS Health (secondary care)</p><p> </p><p> </p><p> </p><p>Since some drugs are prescribed to treat more than one condition and as the condition for which a drug is prescribed is not collected, it is not possible to separate the different conditions for which a drug may have been prescribed. The information provided may therefore include costs from the prescribing of these drugs for conditions other than for osteoporosis.</p><p> </p><p> </p><p> </p><p> </p><p> </p><p><strong> </strong></p><p> </p><p><strong> </strong></p><p> </p><p><strong> </strong></p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 30/10/2014 16:09:20 answering member 4020 label Biography information for George Freeman
	tabling member	4026 label Biography information for Liz Kendall

100721

	registered interest
	date	23/10/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Osteoporosis
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, how much from the publich purse has been spent on research into osteoporosis in each of the last five years.
	tabling member constituency	Leicester West
	tabling member printed	Liz Kendall
	type	WrittenParliamentaryQuestion
	uin	211732
	answer	answer is ministerial correction date of answer 29/10/2014 answer text <p>The following table shows estimated expenditure on research on asthma, motor neurone disease (MND) and osteoporosis by the Medical Research Council, other Research Councils and Innovate UK, and by the National Institute for Health (NIHR) through its research programmes, research centres and units, and research fellowships.</p><p> </p><p> </p><p> </p><p><em>£ million</em></p><p> </p><table><tbody><tr><td> </td><td><p>2009-10</p></td><td><p>2010-11</p></td><td><p>2011-12</p></td><td><p>2012-13</p></td><td><p>2013-14</p></td></tr><tr><td colspan="6"><p>Asthma</p></td></tr><tr><td><p>Medical Research Council</p></td><td><p><del class="ministerial">22.2 </del><ins class="ministerial">6.6</ins></p></td><td><p><del class="ministerial">17.5 </del><ins class="ministerial">5.3</ins></p></td><td><p><del class="ministerial">17.2</del><ins class="ministerial"> 4.5</ins></p></td><td><p><del class="ministerial">19.4</del><ins class="ministerial"> 3.6</ins></p></td><td><p><del class="ministerial">18.8</del><ins class="ministerial"> 5.4</ins></p></td></tr><tr><td><p>Other Research Councils and Innovate UK</p></td><td><p>0.0</p></td><td><p>0.1</p></td><td><p>0.3</p></td><td><p>1.5</p></td><td><p>0.8</p></td></tr><tr><td><p>National Institute for Health Research</p></td><td><p>2.6</p></td><td><p>3.4</p></td><td><p>2.4</p></td><td><p>3.4</p></td><td><p>3.8</p></td></tr><tr><td><p>Total</p></td><td><p><del class="ministerial">24.8</del><ins class="ministerial"> 9.2</ins></p></td><td><p><del class="ministerial">21.0</del><ins class="ministerial"> 8.8</ins></p></td><td><p><del class="ministerial">19.9</del><ins class="ministerial"> 7.2</ins></p></td><td><p><del class="ministerial">24.3 </del><ins class="ministerial">8.5</ins></p></td><td><p><del class="ministerial">23.4</del> <ins class="ministerial">10.0</ins></p></td></tr><tr><td colspan="6"><p>Motor Neurone Research</p></td></tr><tr><td><p>Medical Research Council</p></td><td><p>7.0</p></td><td><p>7.5</p></td><td><p>4.2</p></td><td><p>4.1</p></td><td><p>3.6</p></td></tr><tr><td><p>Other Research Councils and Innovate UK</p></td><td><p>0.2</p></td><td><p>0.2</p></td><td><p>0.4</p></td><td><p>0.7</p></td><td><p>1.0</p></td></tr><tr><td><p>National Institute for Health Research</p></td><td><p>0.1</p></td><td><p>0.1</p></td><td><p>0.4</p></td><td><p>0.7</p></td><td><p>0.5</p></td></tr><tr><td><p>Total</p></td><td><p>7.3</p></td><td><p>7.8</p></td><td><p>5.0</p></td><td><p>5.5</p></td><td><p>5.1</p></td></tr><tr><td colspan="6"><p>Osteoporosis</p></td></tr><tr><td><p>Medical Research Council</p></td><td><p>6.2</p></td><td><p>5.4</p></td><td><p>5.1</p></td><td><p>4.6</p></td><td><p>5.9</p></td></tr><tr><td><p>Other Research Councils and Innovate UK</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.1</p></td><td><p>0.4</p></td><td><p>1.0</p></td></tr><tr><td><p>National Institute for Health Research</p></td><td><p>0.3</p></td><td><p>0.7</p></td><td><p>0.8</p></td><td><p>1.3</p></td><td><p>1.8</p></td></tr><tr><td><p>Total</p></td><td><p>6.5</p></td><td><p>6.1</p></td><td><p>6.0</p></td><td><p>6.3</p></td><td><p>8.7</p></td></tr></tbody></table><p> </p><p> </p><p> </p><p>The figures shown for asthma exclude research into air pollution and potential effects on health outcomes including asthma.</p><p> </p><p> </p><p> </p><p>Total spend by the NIHR on asthma, MND and osteoporosis is higher than the figures shown because expenditure by the NIHR Clinical Research Network (CRN) on these diseases cannot be disaggregated from total CRN expenditure. NIHR expenditure relating to development of new drugs for asthma, MND and osteroporosis occurs primarily through NIHR research infrastructure including the CRN and cannot be disaggregated from total expenditure.</p><p> </p><p> </p><p> </p><p>Information on MRC expenditure into the development of new drugs for asthma, MND or osteoporosis is not available.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 29/10/2014 17:12:28 question first ministerially corrected 13/11/2014 10:22:56 answering member 4020 label Biography information for George Freeman previous answer version 25123 answering member constituency Mid Norfolk answering member printed George Freeman answering member 4020 label Biography information for George Freeman
	tabling member	4026 label Biography information for Liz Kendall

100722

	registered interest
	date	23/10/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Neurology: Nurses
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, how many full-time equivalent specialist nurses for a neurological condition were employed in each region of England in each of the last five years.
	tabling member constituency	Leicester West
	tabling member printed	Liz Kendall
	type	WrittenParliamentaryQuestion
	uin	211733
	answer	answer is ministerial correction date of answer 30/10/2014 answer text <p>The National Health Service annual workforce census provides information on the number of nursing, midwifery and health visiting staff employed in the NHS in England but does not separately identify specialist nurses employed in neurological conditions.</p><p> </p><p> </p><p> </p><p>It is for local NHS organisations with their knowledge of the healthcare needs of their local population to invest in training for specialist skills and to deploy specialist nurses. Specialist nurses provide invaluable support for patients and their families. They are able to provide specialist treatment and advice and act as a gateway to other members of the multidisciplinary team, which can both save the NHS money and, more importantly, improve care and outcomes for patients.</p><p> </p><p> </p><p> </p><p>Health Education England (HEE) supports employers with Continuous Personal and Professional Development. HEE's planning process has created the opportunity for employers, through their membership of local education training boards, to prioritise investment between training the future supply of healthcare professional and the development of existing staff, but it is currently for these local partnerships to identify their relative priorities for investment.</p><p> </p><p> </p><p> </p> answering member constituency Central Suffolk and North Ipswich answering member printed Dr Daniel Poulter question first answered 30/10/2014 16:25:48 answering member 3932 label Biography information for Dr Dan Poulter
	tabling member	4026 label Biography information for Liz Kendall

100723

	registered interest
	date	23/10/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Motor Neurone Disease: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, how much from the public purse has been spent on the development of new drugs to prevent or treat symptoms of motore neurone disease in each of the last five years.
	tabling member constituency	Leicester West
	tabling member printed	Liz Kendall
	type	WrittenParliamentaryQuestion
	uin	211734
	answer	answer is ministerial correction date of answer 29/10/2014 answer text <p>The following table shows estimated expenditure on research on asthma, motor neurone disease (MND) and osteoporosis by the Medical Research Council, other Research Councils and Innovate UK, and by the National Institute for Health (NIHR) through its research programmes, research centres and units, and research fellowships.</p><p> </p><p> </p><p> </p><p><em>£ million</em></p><p> </p><table><tbody><tr><td> </td><td><p>2009-10</p></td><td><p>2010-11</p></td><td><p>2011-12</p></td><td><p>2012-13</p></td><td><p>2013-14</p></td></tr><tr><td colspan="6"><p>Asthma</p></td></tr><tr><td><p>Medical Research Council</p></td><td><p><del class="ministerial">22.2 </del><ins class="ministerial">6.6</ins></p></td><td><p><del class="ministerial">17.5 </del><ins class="ministerial">5.3</ins></p></td><td><p><del class="ministerial">17.2</del><ins class="ministerial"> 4.5</ins></p></td><td><p><del class="ministerial">19.4</del><ins class="ministerial"> 3.6</ins></p></td><td><p><del class="ministerial">18.8</del><ins class="ministerial"> 5.4</ins></p></td></tr><tr><td><p>Other Research Councils and Innovate UK</p></td><td><p>0.0</p></td><td><p>0.1</p></td><td><p>0.3</p></td><td><p>1.5</p></td><td><p>0.8</p></td></tr><tr><td><p>National Institute for Health Research</p></td><td><p>2.6</p></td><td><p>3.4</p></td><td><p>2.4</p></td><td><p>3.4</p></td><td><p>3.8</p></td></tr><tr><td><p>Total</p></td><td><p><del class="ministerial">24.8</del><ins class="ministerial"> 9.2</ins></p></td><td><p><del class="ministerial">21.0</del><ins class="ministerial"> 8.8</ins></p></td><td><p><del class="ministerial">19.9</del><ins class="ministerial"> 7.2</ins></p></td><td><p><del class="ministerial">24.3 </del><ins class="ministerial">8.5</ins></p></td><td><p><del class="ministerial">23.4</del> <ins class="ministerial">10.0</ins></p></td></tr><tr><td colspan="6"><p>Motor Neurone Research</p></td></tr><tr><td><p>Medical Research Council</p></td><td><p>7.0</p></td><td><p>7.5</p></td><td><p>4.2</p></td><td><p>4.1</p></td><td><p>3.6</p></td></tr><tr><td><p>Other Research Councils and Innovate UK</p></td><td><p>0.2</p></td><td><p>0.2</p></td><td><p>0.4</p></td><td><p>0.7</p></td><td><p>1.0</p></td></tr><tr><td><p>National Institute for Health Research</p></td><td><p>0.1</p></td><td><p>0.1</p></td><td><p>0.4</p></td><td><p>0.7</p></td><td><p>0.5</p></td></tr><tr><td><p>Total</p></td><td><p>7.3</p></td><td><p>7.8</p></td><td><p>5.0</p></td><td><p>5.5</p></td><td><p>5.1</p></td></tr><tr><td colspan="6"><p>Osteoporosis</p></td></tr><tr><td><p>Medical Research Council</p></td><td><p>6.2</p></td><td><p>5.4</p></td><td><p>5.1</p></td><td><p>4.6</p></td><td><p>5.9</p></td></tr><tr><td><p>Other Research Councils and Innovate UK</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.1</p></td><td><p>0.4</p></td><td><p>1.0</p></td></tr><tr><td><p>National Institute for Health Research</p></td><td><p>0.3</p></td><td><p>0.7</p></td><td><p>0.8</p></td><td><p>1.3</p></td><td><p>1.8</p></td></tr><tr><td><p>Total</p></td><td><p>6.5</p></td><td><p>6.1</p></td><td><p>6.0</p></td><td><p>6.3</p></td><td><p>8.7</p></td></tr></tbody></table><p> </p><p> </p><p> </p><p>The figures shown for asthma exclude research into air pollution and potential effects on health outcomes including asthma.</p><p> </p><p> </p><p> </p><p>Total spend by the NIHR on asthma, MND and osteoporosis is higher than the figures shown because expenditure by the NIHR Clinical Research Network (CRN) on these diseases cannot be disaggregated from total CRN expenditure. NIHR expenditure relating to development of new drugs for asthma, MND and osteroporosis occurs primarily through NIHR research infrastructure including the CRN and cannot be disaggregated from total expenditure.</p><p> </p><p> </p><p> </p><p>Information on MRC expenditure into the development of new drugs for asthma, MND or osteoporosis is not available.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 29/10/2014 17:12:28 question first ministerially corrected 13/11/2014 10:22:56 answering member 4020 label Biography information for George Freeman previous answer version 25123 answering member constituency Mid Norfolk answering member printed George Freeman answering member 4020 label Biography information for George Freeman
	tabling member	4026 label Biography information for Liz Kendall

100724

	registered interest
	date	23/10/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Motor Neurone Disease: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, how much has been spent on the prescription of drugs for the treatment of motor neurone disease in each of the last five years.
	tabling member constituency	Leicester West
	tabling member printed	Liz Kendall
	type	WrittenParliamentaryQuestion
	uin	211727
	answer	answer is ministerial correction date of answer 30/10/2014 answer text <p>Information on National Health Service expenditure on drugs for the treatment of motor neurone disease in primary and secondary care is in the table.</p><p> </p><p><strong> </strong></p><p> </p><p>Riluzole is the only drug defined in the British National Formulary as being used for the treatment of motor neurone disease</p><p> </p><p> </p><p> </p><table><tbody><tr><td colspan="3"><p>Cost of riluzole, England<sup>1</sup></p></td></tr><tr><td><p>Year</p></td><td><p>Primary Care</p><p>(£ million)</p></td><td><p>Secondary Care</p><p>(£ million)</p></td></tr><tr><td><p>2009</p></td><td><p>3.8</p></td><td><p>1.2</p></td></tr><tr><td><p>2010</p></td><td><p>4.9</p></td><td><p>1.4</p></td></tr><tr><td><p>2011</p></td><td><p>5.5</p></td><td><p>1.4</p></td></tr><tr><td><p>2012</p></td><td><p>5.8</p></td><td><p>1.5</p></td></tr><tr><td><p>2013<sup>2</sup></p></td><td><p>2.3</p></td><td><p>1.0</p></td></tr></tbody></table><p> </p><p><sup>1</sup> Cost of drugs at NHS list price. It does not take account of discounts, dispensing costs, fees or prescription charges income.</p><p> </p><p><sup>2 </sup>The patent for riluzole expired in the first quarter of 2013.</p><p> </p><p><em>Source: </em></p><p> </p><p>Prescription Cost Analysis (PCA) provided by the Health and Social Care Information Centre (primary care)</p><p> </p><p>Hospital Pharmacy Audit Index (HPAI) provided by IMS Health (secondary care)</p><p> </p><p> </p><p> </p><p>Since a drug could be prescribed to treat more than one condition and as the condition for which a drug is prescribed is not collected, it is not possible to separate the different conditions for which it may have been prescribed. The information provided may therefore include costs from the prescribing of the drug for conditions other than for motor neurone disease.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 30/10/2014 16:04:31 answering member 4020 label Biography information for George Freeman
	tabling member	4026 label Biography information for Liz Kendall

100726

	registered interest
	date	23/10/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Health Services
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, how many clinical commissioning groups in England provide some form of falls service.
	tabling member constituency	Leicester West
	tabling member printed	Liz Kendall
	type	WrittenParliamentaryQuestion
	uin	211728
	answer	answer is ministerial correction date of answer 30/10/2014 answer text <p>The provision of fracture liaison services (FLS) and falls services is a matter for local clinical commissioning groups (CCGs) and data on numbers is not collected centrally. NHS England advises that it is aware that provision of good FLS is not uniform across the country and is working with CCGs to support them to develop appropriate local services. It also advises that the FLS model recommended by the International Osteoporosis Foundation and the National Osteoporosis society is recognised as best practice and is being promoted. In addition to this, the guidance from the National Institute for Health and Care Excellence (NICE) ‘Falls: assessment and prevention of falls in older people’ sets out best practice for clinicians on the management of patients aged 65 and over who are susceptible to falls.</p><p> </p><p> </p><p> </p><p>Regarding the cost to the National Health Service of treating fractures attributable to osteoporosis, whilst programme budgeting data provides figures for annual NHS spend on musculoskeletal services in England, the cost of treating individual musculoskeletal conditions, such as osteoporosis or specific services such as FLS, is not available as part of this.</p><p> </p><p> </p><p> </p><p>Information concerning the number of people affected by osteoporosis in each of the last five years is not collected. NICE estimates that over 300,000 patients present with fragility fractures to hospitals in the United Kingdom each year.</p><p> </p><p> </p><p> </p><p> </p><p> </p> answering member constituency North Norfolk answering member printed Norman Lamb grouped question UIN 211736 211737 211738 211740 question first answered 30/10/2014 16:37:15 answering member 1439 label Biography information for Norman Lamb
	tabling member	4026 label Biography information for Liz Kendall

100728

	registered interest
	date	23/10/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Motor Neurone Disease
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, how much from the public purse has been spent on research into motor neurone disease in each of the last five years.
	tabling member constituency	Leicester West
	tabling member printed	Liz Kendall
	type	WrittenParliamentaryQuestion
	uin	211730
	answer	answer is ministerial correction date of answer 29/10/2014 answer text <p>The following table shows estimated expenditure on research on asthma, motor neurone disease (MND) and osteoporosis by the Medical Research Council, other Research Councils and Innovate UK, and by the National Institute for Health (NIHR) through its research programmes, research centres and units, and research fellowships.</p><p> </p><p> </p><p> </p><p><em>£ million</em></p><p> </p><table><tbody><tr><td> </td><td><p>2009-10</p></td><td><p>2010-11</p></td><td><p>2011-12</p></td><td><p>2012-13</p></td><td><p>2013-14</p></td></tr><tr><td colspan="6"><p>Asthma</p></td></tr><tr><td><p>Medical Research Council</p></td><td><p><del class="ministerial">22.2 </del><ins class="ministerial">6.6</ins></p></td><td><p><del class="ministerial">17.5 </del><ins class="ministerial">5.3</ins></p></td><td><p><del class="ministerial">17.2</del><ins class="ministerial"> 4.5</ins></p></td><td><p><del class="ministerial">19.4</del><ins class="ministerial"> 3.6</ins></p></td><td><p><del class="ministerial">18.8</del><ins class="ministerial"> 5.4</ins></p></td></tr><tr><td><p>Other Research Councils and Innovate UK</p></td><td><p>0.0</p></td><td><p>0.1</p></td><td><p>0.3</p></td><td><p>1.5</p></td><td><p>0.8</p></td></tr><tr><td><p>National Institute for Health Research</p></td><td><p>2.6</p></td><td><p>3.4</p></td><td><p>2.4</p></td><td><p>3.4</p></td><td><p>3.8</p></td></tr><tr><td><p>Total</p></td><td><p><del class="ministerial">24.8</del><ins class="ministerial"> 9.2</ins></p></td><td><p><del class="ministerial">21.0</del><ins class="ministerial"> 8.8</ins></p></td><td><p><del class="ministerial">19.9</del><ins class="ministerial"> 7.2</ins></p></td><td><p><del class="ministerial">24.3 </del><ins class="ministerial">8.5</ins></p></td><td><p><del class="ministerial">23.4</del> <ins class="ministerial">10.0</ins></p></td></tr><tr><td colspan="6"><p>Motor Neurone Research</p></td></tr><tr><td><p>Medical Research Council</p></td><td><p>7.0</p></td><td><p>7.5</p></td><td><p>4.2</p></td><td><p>4.1</p></td><td><p>3.6</p></td></tr><tr><td><p>Other Research Councils and Innovate UK</p></td><td><p>0.2</p></td><td><p>0.2</p></td><td><p>0.4</p></td><td><p>0.7</p></td><td><p>1.0</p></td></tr><tr><td><p>National Institute for Health Research</p></td><td><p>0.1</p></td><td><p>0.1</p></td><td><p>0.4</p></td><td><p>0.7</p></td><td><p>0.5</p></td></tr><tr><td><p>Total</p></td><td><p>7.3</p></td><td><p>7.8</p></td><td><p>5.0</p></td><td><p>5.5</p></td><td><p>5.1</p></td></tr><tr><td colspan="6"><p>Osteoporosis</p></td></tr><tr><td><p>Medical Research Council</p></td><td><p>6.2</p></td><td><p>5.4</p></td><td><p>5.1</p></td><td><p>4.6</p></td><td><p>5.9</p></td></tr><tr><td><p>Other Research Councils and Innovate UK</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.1</p></td><td><p>0.4</p></td><td><p>1.0</p></td></tr><tr><td><p>National Institute for Health Research</p></td><td><p>0.3</p></td><td><p>0.7</p></td><td><p>0.8</p></td><td><p>1.3</p></td><td><p>1.8</p></td></tr><tr><td><p>Total</p></td><td><p>6.5</p></td><td><p>6.1</p></td><td><p>6.0</p></td><td><p>6.3</p></td><td><p>8.7</p></td></tr></tbody></table><p> </p><p> </p><p> </p><p>The figures shown for asthma exclude research into air pollution and potential effects on health outcomes including asthma.</p><p> </p><p> </p><p> </p><p>Total spend by the NIHR on asthma, MND and osteoporosis is higher than the figures shown because expenditure by the NIHR Clinical Research Network (CRN) on these diseases cannot be disaggregated from total CRN expenditure. NIHR expenditure relating to development of new drugs for asthma, MND and osteroporosis occurs primarily through NIHR research infrastructure including the CRN and cannot be disaggregated from total expenditure.</p><p> </p><p> </p><p> </p><p>Information on MRC expenditure into the development of new drugs for asthma, MND or osteoporosis is not available.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 29/10/2014 17:12:28 question first ministerially corrected 13/11/2014 10:22:56 answering member 4020 label Biography information for George Freeman previous answer version 25123 answering member constituency Mid Norfolk answering member printed George Freeman answering member 4020 label Biography information for George Freeman
	tabling member	4026 label Biography information for Liz Kendall

100729

	registered interest
	date	23/10/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Osteoporosis
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, how many (a) men under the age of 18, (b) women under the age of 18, (c) men between the ages of 18 and 60, (d) women between the ages of 18 and 60, (e) men over the age of 60 and (f) women over the age of 60 have been diagnosed with osteoporosis in each of the last five years.
	tabling member constituency	Leicester West
	tabling member printed	Liz Kendall
	type	WrittenParliamentaryQuestion
	uin	211737
	answer	answer is ministerial correction date of answer 30/10/2014 answer text <p>The provision of fracture liaison services (FLS) and falls services is a matter for local clinical commissioning groups (CCGs) and data on numbers is not collected centrally. NHS England advises that it is aware that provision of good FLS is not uniform across the country and is working with CCGs to support them to develop appropriate local services. It also advises that the FLS model recommended by the International Osteoporosis Foundation and the National Osteoporosis society is recognised as best practice and is being promoted. In addition to this, the guidance from the National Institute for Health and Care Excellence (NICE) ‘Falls: assessment and prevention of falls in older people’ sets out best practice for clinicians on the management of patients aged 65 and over who are susceptible to falls.</p><p> </p><p> </p><p> </p><p>Regarding the cost to the National Health Service of treating fractures attributable to osteoporosis, whilst programme budgeting data provides figures for annual NHS spend on musculoskeletal services in England, the cost of treating individual musculoskeletal conditions, such as osteoporosis or specific services such as FLS, is not available as part of this.</p><p> </p><p> </p><p> </p><p>Information concerning the number of people affected by osteoporosis in each of the last five years is not collected. NICE estimates that over 300,000 patients present with fragility fractures to hospitals in the United Kingdom each year.</p><p> </p><p> </p><p> </p><p> </p><p> </p> answering member constituency North Norfolk answering member printed Norman Lamb grouped question UIN 211728 211736 211738 211740 question first answered 30/10/2014 16:37:15 answering member 1439 label Biography information for Norman Lamb
	tabling member	4026 label Biography information for Liz Kendall

100730

	registered interest
	date	23/10/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Osteoporosis: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, how much from the public purse has been spent on the development of new drugs to treat symptoms of osteoporosis in each of the last five years.
	tabling member constituency	Leicester West
	tabling member printed	Liz Kendall
	type	WrittenParliamentaryQuestion
	uin	211735
	answer	answer is ministerial correction date of answer 29/10/2014 answer text <p>The following table shows estimated expenditure on research on asthma, motor neurone disease (MND) and osteoporosis by the Medical Research Council, other Research Councils and Innovate UK, and by the National Institute for Health (NIHR) through its research programmes, research centres and units, and research fellowships.</p><p> </p><p> </p><p> </p><p><em>£ million</em></p><p> </p><table><tbody><tr><td> </td><td><p>2009-10</p></td><td><p>2010-11</p></td><td><p>2011-12</p></td><td><p>2012-13</p></td><td><p>2013-14</p></td></tr><tr><td colspan="6"><p>Asthma</p></td></tr><tr><td><p>Medical Research Council</p></td><td><p><del class="ministerial">22.2 </del><ins class="ministerial">6.6</ins></p></td><td><p><del class="ministerial">17.5 </del><ins class="ministerial">5.3</ins></p></td><td><p><del class="ministerial">17.2</del><ins class="ministerial"> 4.5</ins></p></td><td><p><del class="ministerial">19.4</del><ins class="ministerial"> 3.6</ins></p></td><td><p><del class="ministerial">18.8</del><ins class="ministerial"> 5.4</ins></p></td></tr><tr><td><p>Other Research Councils and Innovate UK</p></td><td><p>0.0</p></td><td><p>0.1</p></td><td><p>0.3</p></td><td><p>1.5</p></td><td><p>0.8</p></td></tr><tr><td><p>National Institute for Health Research</p></td><td><p>2.6</p></td><td><p>3.4</p></td><td><p>2.4</p></td><td><p>3.4</p></td><td><p>3.8</p></td></tr><tr><td><p>Total</p></td><td><p><del class="ministerial">24.8</del><ins class="ministerial"> 9.2</ins></p></td><td><p><del class="ministerial">21.0</del><ins class="ministerial"> 8.8</ins></p></td><td><p><del class="ministerial">19.9</del><ins class="ministerial"> 7.2</ins></p></td><td><p><del class="ministerial">24.3 </del><ins class="ministerial">8.5</ins></p></td><td><p><del class="ministerial">23.4</del> <ins class="ministerial">10.0</ins></p></td></tr><tr><td colspan="6"><p>Motor Neurone Research</p></td></tr><tr><td><p>Medical Research Council</p></td><td><p>7.0</p></td><td><p>7.5</p></td><td><p>4.2</p></td><td><p>4.1</p></td><td><p>3.6</p></td></tr><tr><td><p>Other Research Councils and Innovate UK</p></td><td><p>0.2</p></td><td><p>0.2</p></td><td><p>0.4</p></td><td><p>0.7</p></td><td><p>1.0</p></td></tr><tr><td><p>National Institute for Health Research</p></td><td><p>0.1</p></td><td><p>0.1</p></td><td><p>0.4</p></td><td><p>0.7</p></td><td><p>0.5</p></td></tr><tr><td><p>Total</p></td><td><p>7.3</p></td><td><p>7.8</p></td><td><p>5.0</p></td><td><p>5.5</p></td><td><p>5.1</p></td></tr><tr><td colspan="6"><p>Osteoporosis</p></td></tr><tr><td><p>Medical Research Council</p></td><td><p>6.2</p></td><td><p>5.4</p></td><td><p>5.1</p></td><td><p>4.6</p></td><td><p>5.9</p></td></tr><tr><td><p>Other Research Councils and Innovate UK</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.1</p></td><td><p>0.4</p></td><td><p>1.0</p></td></tr><tr><td><p>National Institute for Health Research</p></td><td><p>0.3</p></td><td><p>0.7</p></td><td><p>0.8</p></td><td><p>1.3</p></td><td><p>1.8</p></td></tr><tr><td><p>Total</p></td><td><p>6.5</p></td><td><p>6.1</p></td><td><p>6.0</p></td><td><p>6.3</p></td><td><p>8.7</p></td></tr></tbody></table><p> </p><p> </p><p> </p><p>The figures shown for asthma exclude research into air pollution and potential effects on health outcomes including asthma.</p><p> </p><p> </p><p> </p><p>Total spend by the NIHR on asthma, MND and osteoporosis is higher than the figures shown because expenditure by the NIHR Clinical Research Network (CRN) on these diseases cannot be disaggregated from total CRN expenditure. NIHR expenditure relating to development of new drugs for asthma, MND and osteroporosis occurs primarily through NIHR research infrastructure including the CRN and cannot be disaggregated from total expenditure.</p><p> </p><p> </p><p> </p><p>Information on MRC expenditure into the development of new drugs for asthma, MND or osteoporosis is not available.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 29/10/2014 17:12:28 question first ministerially corrected 13/11/2014 10:22:56 answering member 4020 label Biography information for George Freeman previous answer version 25123 answering member constituency Mid Norfolk answering member printed George Freeman answering member 4020 label Biography information for George Freeman
	tabling member	4026 label Biography information for Liz Kendall